Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement

 
• By Derrick Gingery

Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.

FDA vaccines advisory committee meeting screenshot
The Vaccines and Related Biological Products Advisory Committee vote on the Novavax COVID-19 vaccine is announced during the 7 June meeting. • Source: Screenshot

More from US FDA Performance Tracker

More from Regulatory Trackers